{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:20:26Z","timestamp":1785316826621,"version":"3.55.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Dr. Behzad Poopak"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Tyrosine kinase inhibitors (TKIs) are considered standard first-line treatment in patients with chronic myeloid leukemia. Because ABL kinase domain mutations are the most common causes of treatment resistance, their prevalence and assessment during treatment may predict subsequent response to therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The molecular response in Bcr-Abl1IS was tested via quantitative real-time polymerase chain reaction. We used the direct sequencing technique to discover the mutations in the ABL kinase domain. The IRIS trial established a standard baseline for measurement \u2013 (100% BCR-ABL1 on the \u2018international scale\u2019) and a major molecular response (good response to therapy) was defined as a 3-log reduction in the amount of BCR-ABL1 \u2013 0.1% BCR-ABL1 on the international scale.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We observed 11 different mutations in 13 patients, including E255K, which had the highest mutation rate. A lack of hematologic response was found in 22 patients, who showed a significantly higher incidence of mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Detection of kinase domain mutations is a reliable method for choosing the best treatment strategy based on patients\u2019 conditions, avoiding ineffective treatments, and running high-cost protocols in patients with acquired resistance to TKIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmaa052","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T11:11:58Z","timestamp":1592478718000},"page":"158-167","source":"Crossref","is-referenced-by-count":3,"title":["ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors"],"prefix":"10.1093","volume":"52","author":[{"given":"Mahboobeh","family":"Shojaei","sequence":"first","affiliation":[{"name":"Iranian Blood Transfusion Organization, High Institute of Research and Education in Transfusion Medicine, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Center, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita","family":"Azarkeivan","sequence":"additional","affiliation":[{"name":"Iranian Blood Transfusion Organization, High Institute of Research and Education in Transfusion Medicine, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Poopak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, IR Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"issue":"4","key":"2021031518102919100_CIT0001","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4274\/Tjh.2013.0151","article-title":"Turkish chronic myeloid leukemia study: retrospective sectional analysis of CML patients","volume":"30","author":"Sahin","year":"2013","journal-title":"Turk J Haematol."},{"issue":"6","key":"2021031518102919100_CIT0002","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s13402-015-0248-2","article-title":"Inhibition of Ras-mediated signaling pathways in CML stem cells","volume":"38","author":"Bertacchini","year":"2015","journal-title":"Cell Oncol (Dordr)."},{"issue":"8","key":"2021031518102919100_CIT0003","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bph.12183","article-title":"Targeting survival pathways in chronic myeloid leukaemia stem cells","volume":"169","author":"Sinclair","year":"2013","journal-title":"Br J Pharmacol."},{"issue":"11","key":"2021031518102919100_CIT0004","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1007\/s13277-014-2610-9","article-title":"New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia","volume":"35","author":"Shahrabi","year":"2014","journal-title":"Tumour Biol."},{"issue":"1","key":"2021031518102919100_CIT0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am J Med."},{"issue":"3","key":"2021031518102919100_CIT0006","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood."},{"key":"2021031518102919100_CIT0007","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1007\/s00277-015-2323-1","article-title":"Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients","volume":"94","author":"Hochhaus","year":"2015","journal-title":"Ann Hematol."},{"issue":"6","key":"2021031518102919100_CIT0008","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2021031518102919100_CIT0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk Res."},{"issue":"3","key":"2021031518102919100_CIT0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit Rev Oncol Hematol."},{"issue":"March","key":"2021031518102919100_CIT0011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov Today Technol."},{"issue":"1","key":"2021031518102919100_CIT0012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood."},{"issue":"1","key":"2021031518102919100_CIT0013","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood."},{"issue":"11","key":"2021031518102919100_CIT0014","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood."},{"issue":"1","key":"2021031518102919100_CIT0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","article-title":"Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history","volume":"24","author":"Jabbour","year":"2010","journal-title":"Leukemia."},{"issue":"5","key":"2021031518102919100_CIT0016","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/jhg.2015.11","article-title":"Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib","volume":"60","author":"Rostami","year":"2015","journal-title":"J Hum Genet."},{"issue":"5531","key":"2021031518102919100_CIT0017","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science."},{"issue":"11","key":"2021031518102919100_CIT0018","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia."},{"key":"2021031518102919100_CIT0019","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/asheducation-2013.1.168","article-title":"Which TKI? An embarrassment of riches for chronic myeloid leukemia patients","volume":"2013","author":"Hughes","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"1","key":"2021031518102919100_CIT0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.23864","article-title":"ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?","volume":"90","author":"Etienne","year":"2015","journal-title":"Am J Hematol."},{"issue":"3","key":"2021031518102919100_CIT0021","doi-asserted-by":"crossref","first-page":"e2334","DOI":"10.17795\/ijcp2334","article-title":"Characterizing of four common BCR-ABL kinase domain mutations (T315I, Y253H, M351T and E255K) in Iranian chronic myelogenous leukemia patients with imatinib resistance","volume":"8","author":"Rejali","year":"2015","journal-title":"Iran J Cancer Prev."},{"issue":"29","key":"2021031518102919100_CIT0022","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol."},{"issue":"9","key":"2021031518102919100_CIT0023","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood."},{"issue":"2","key":"2021031518102919100_CIT0024","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell."},{"issue":"18","key":"2021031518102919100_CIT0025","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","article-title":"ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol."},{"issue":"24","key":"2021031518102919100_CIT0026","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2021031518102919100_CIT0027","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1007\/s13277-014-1926-9","article-title":"Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India","volume":"35","author":"Kagita","year":"2014","journal-title":"Tumour Biol."},{"issue":"1","key":"2021031518102919100_CIT0028","doi-asserted-by":"crossref","first-page":"e0114828","DOI":"10.1371\/journal.pone.0114828","article-title":"Evolution of BCR\/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor","volume":"10","author":"Vaidya","year":"2015","journal-title":"PLoS One."},{"issue":"9","key":"2021031518102919100_CIT0029","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood."},{"issue":"3","key":"2021031518102919100_CIT0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia."},{"issue":"9","key":"2021031518102919100_CIT0031","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/07357907.2015.1065499","article-title":"BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival","volume":"33","author":"Pagnano","year":"2015","journal-title":"Cancer Invest."},{"issue":"3","key":"2021031518102919100_CIT0032","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.medcli.2012.10.028","article-title":"Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors","volume":"141","author":"Marc\u00e9","year":"2013","journal-title":"Med Clin (Barc)."},{"issue":"4","key":"2021031518102919100_CIT0033","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.leukres.2013.12.025","article-title":"BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients\u2014frequency and clinical outcome","volume":"38","author":"Elias","year":"2014","journal-title":"Leuk Res."},{"issue":"12","key":"2021031518102919100_CIT0034","first-page":"789","article-title":"Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib","volume":"119","author":"Lewandowski","year":"2009","journal-title":"Polskie Archiwum Medycyny Wewn\u0119trznej."},{"issue":"3","key":"2021031518102919100_CIT0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1179\/1607845412Y.0000000050","article-title":"Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance","volume":"18","author":"Chahardouli","year":"2013","journal-title":"Hematology."},{"issue":"20","key":"2021031518102919100_CIT0036","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi (\u03c6)-LMC GROUP)","volume":"6","author":"Nicolini","year":"2006","journal-title":"Leukemia."},{"issue":"18","key":"2021031518102919100_CIT0037","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","article-title":"Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"121","author":"Hochhaus","year":"2013","journal-title":"Blood."},{"issue":"3","key":"2021031518102919100_CIT0038","first-page":"1022","article-title":"BCR-ABL point mutations and TKI treatment in CML patients","volume":"2","author":"Kimura","year":"2014","journal-title":"J Hematol Transf."},{"key":"2021031518102919100_CIT0039","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol."},{"issue":"7","key":"2021031518102919100_CIT0040","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood."},{"issue":"12","key":"2021031518102919100_CIT0041","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood."},{"issue":"9","key":"2021031518102919100_CIT0042","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hughes","year":"2015","journal-title":"Leukemia."},{"issue":"8","key":"2021031518102919100_CIT0043","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1101\/gr.10.8.1249","article-title":"Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing","volume":"10","author":"Alderborn","year":"2000","journal-title":"Genome Res."},{"issue":"2","key":"2021031518102919100_CIT0044","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica."},{"issue":"3","key":"2021031518102919100_CIT0045","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.clml.2013.11.002","article-title":"Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib","volume":"14","author":"Lau","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/labmed\/article-pdf\/52\/2\/158\/36603572\/lmaa052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/labmed\/article-pdf\/52\/2\/158\/36603572\/lmaa052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T18:11:48Z","timestamp":1615831908000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/52\/2\/158\/5895286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,21]]},"published-print":{"date-parts":[[2021,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmaa052","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,8,21]]}}}